Study comparing standard dose and high-dose imatinib mesylate in patients with chronic phase Ph+ CML.

Trial Profile

Study comparing standard dose and high-dose imatinib mesylate in patients with chronic phase Ph+ CML.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2012 Planned end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 23 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top